Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11775068 | 0.98 | SIRT2 (0.42) | SIRT2GAALMNAALDH1A1HSD17B10 | |
| SCHEMBL8413376 | 0.98 | SIRT2 (0.42) | SIRT2GAALMNAALDH1A1HSD17B10 | |
| SCHEMBL11773588 | 0.98 | SIRT2 (0.42) | SIRT2GAALMNAALDH1A1HSD17B10 | |
| SCHEMBL11607014 | 0.98 | SIRT2 (0.42) | SIRT2GAALMNAALDH1A1HSD17B10 | |
| SCHEMBL11779345 | 0.98 | SIRT2 (0.42) | SIRT2GAALMNAALDH1A1HSD17B10 | |
| SCHEMBL28179569 | 0.93 | GAA (0.36) | SIRT2GAASMN1; SMN2CETPOPRM1 | |
| SCHEMBL11351135 | 0.91 | GAA (0.37) | SIRT2GAASMN1; SMN2CETPOPRM1 | |
| SCHEMBL4359771 | 0.89 | GAA (0.40) | SIRT2GAASMN1; SMN2OPRM1OPRL1 | |
| Hexane SCHEMBL28832412 | 0.89 | SMN1; SMN2 (0.39) | SIRT2GAASMN1; SMN2LMNAALDH1A1 | |
| Decane SCHEMBL3423075 | 0.86 | LMNA (0.42) | SIRT2GAASMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260096771-A1 | Multi-Layer Contact Patch to Perform an Allergen Diagnostic | EVME INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20220378362-A1 | APPARATUS TO PERFORM AN ALLERGEN DIAGNOSTIC | EVME INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220370000-A1 | APPARATUS TO PERFORM AN ALLERGEN DIAGNOSTIC | EVME INC. | 2022-11-24 | — | — | US | disclosed |
| CN-101811985-B | Method for producing pentylcyclohexylbiphenylcarbonitrile | JIANSU LIANHE CHEMICAL CO LTD | 2013-09-25 | — | — | CN | disclosed |
| EP-2528907-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-8299068-B2 | Therapeutically active cyclopentanes | ALLERGAN, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094225-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| CN-101811985-A | Method for producing pentylcyclohexylbiphenylcarbonitrile | JIANGSU KANGXIANG GROUP COMPANY | 2010-08-25 | — | — | CN | disclosed |
| EP-0860455-B1 | Photocrosslinkable polymers | ROLIC AG (CH) | 2008-06-04 | — | — | EP | disclosed |
| US-6632909-B2 | Alkylenedi- acrylates and acrylamides containing phenyl groups substituted with at least two alkoxy or fluoroalkoxy groups; use in orientation layers for liquid crystals, and in optical components, in particular hybrid layer elements. | ROLIC AG (CH) | 2003-10-14 | — | — | US | disclosed |
| US-20020061996-A1 | Photocrosslinkable polymers | BUCHECKER RICHARD (CH) | 2002-05-23 | — | — | US | disclosed |
| EP-0860455-A2 | Photocrosslinkable polymers | Rolic AG (CH) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096771-A1 | Multi-Layer Contact Patch to Perform an Allergen Diagnostic | EPCAM, CUTA, CD63 | SIRT2 3922/4885GAA 3767/4885SMN1; SMN2 4162/4885 |
| US-20110190286-A1 | THERAPEUTICALLY ACTIVE CYCLOPENTANES | TUBB6, ANXA5, TUBB1 | SIRT2 2642/4885GAA 147/4885SMN1; SMN2 2479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.